-
Media Release
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
-
Media Release
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
-
Media Release
Novartis' heart failure medicine LCZ696 granted FDA priority review
-
Media Release
Novartis' heart failure medicine LCZ696 granted FDA priority review
-
Media Release
Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients
-
Media Release
Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients
-
Media Release
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
-
Media Release
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
-
Media Release
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
-
Media Release
Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
-
Media Release
Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
-
Media Release
Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients